Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2901 to 2950 of 3761 results for treatment

  1. Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment (IPG772)

    We have moved interventional procedures guidance 772 to become HealthTech guidance 693. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  3. Narrow band imaging for Barrett's oesophagus (MIB179)

    NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .

    Medtech innovation briefing
    Published
    29 March 2019

  4. Aspirin prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur:- What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?

    deliver the injection. Patient adherence to treatment may be improved with anoral rather than injectable treatment.A large...

    Research recommendation
    Published
    15 November 2018

  5. There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents. Any...

    Research recommendation
    Published
    9 June 2015

  6. Social and emotional wellbeing: early years (PH40)

    This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.

    Public health guideline
    Published
    24 October 2012
    View recommendations

    Sections for PH40

  7. Saliva:- How is excessive drooling of saliva (sialorrhoea) managed in people with motor neurone disease (MND)?

    no evidence base for clinicians to make decisions with regards to the treatment options available. Antimuscarinics are used first-line...

    Research recommendation
    Published
    21 March 2016

  8. Helge for detecting haemolysis (MIB225)

    NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .

    Medtech innovation briefing
    Published
    1 September 2020

  9. Which patient groups, contamination groups and which layers gain the most benefit from the use of triclosan-coated or triclosan-impregnated sutures?

    experiencing wound dehiscence following surgery, which may reduce the costs of treatment. However, the committee acknowledged that there...

    Research recommendation
    Published
    16 August 2019

  10. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  11. Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)

    Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.

    HealthTech guidance
    Last updated
    21 September 2022
    View recommendations

    Sections for HTG486

  12. Our principles

    The principles that guide the development of NICE guidance and standards.

  13. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  14. SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea (MIB190)

    NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .

    Medtech innovation briefing
    Published
    9 September 2019

  15. Comparison between expectant, medical or surgical management of ectopic pregnancy: In women with ectopic pregnancy, does the type of intervention impact on women's experience, including psychological and emotional outcomes?

    there is no evidence exploring the psychological impact of the different treatments for ectopic pregnancy. However, the emotional impact...

    Research recommendation
    Published
    17 December 2021

  16. VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest (HTG765)

    Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.

    HealthTech guidance
    Published
    22 October 2025
    View recommendations

    Sections for HTG765

  17. Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (MTG10)

    We have moved medical technologies guidance 10 to become HealthTech guidance 287. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  18. Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (TA150)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 242.

    Withdrawn guidance

  19. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Withdrawn guidance

  20. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    potentially improve survival if people recover enough to have more effective cancer treatments. The outcomes of interest are:-...

    Research recommendation
    Published
    14 November 2018

  21. Current evidence on the safety and efficacy of electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease (GORD) is limited in quantity and quality. Therefore, this procedure should only be used in the context of research.

    description of patient selection, and details of adjunctive medical and surgical treatments. Outcomes should include GORD symptoms,...

    Research recommendation
    Published
    25 January 2016

  22. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

    Medtech innovation briefing
    Published
    7 March 2017

  23. Multiple pregnancy: twin and triplet pregnancies (QS46)

    This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    4 September 2019
    View quality statements

    Sections for QS46

  24. Medicines management for people receiving social care in the community (QS171)

    This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    24 July 2018
    View quality statements

    Sections for QS171

  25. Autism spectrum disorder in adults: diagnosis and management (CG142)

    This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.

    Clinical guideline
    Last updated
    14 June 2021
    View recommendations

    Sections for CG142

  26. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  27. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Withdrawn guidance

  28. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

    NICE guideline
    Published
    21 March 2024
    View recommendations

    Sections for NG241

  29. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  30. Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome (IPG198)

    We have moved interventional procedures guidance 198 to become HealthTech guidance 126. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  31. Second-generation endometrial ablation for HMB associated with myometrial pathology:- Are outcomes after second-generation endometrial ablation for women with HMB associated with myometrial pathology (adenomyosis and/or uterine fibroids) equivalent to those for women without myometrial pathology?

    common uterine pathologies in women presenting with HMB. Pharmacological treatments appear to be less effective in the presence of these...

    Research recommendation
    Published
    14 November 2018

  32. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.

    HealthTech guidance
    Published
    27 August 2025
    View recommendations

    Sections for HTG759

  33. Lifestyle interventions (diet and exercise):- Are specialist lifestyle interventions (diet and exercise) effective, compared with no specialist lifestyle interventions, for women with endometriosis?

    the condition and ways of managing it that support surgical and medical treatment. However, no high-quality research was identified on...

    Research recommendation
    Published
    15 October 2018

  34. Pain management programmes:- Are pain management programmes a clinically and cost-effective intervention for women with endometriosis?

    Furthermore, pain management programmes have not been compared with other treatments available for endometriosis. Pain management...

    Research recommendation
    Published
    15 October 2018

  35. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development Reference number: GID-TA10843 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (IPG711)

    We have moved interventional procedures guidance 711 to become HealthTech guidance 599. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  37. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

    This guidance has been updated and replaced by NICE technology appraisal guidance 784.

    Withdrawn guidance

  38. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  39. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Withdrawn guidance

  40. Strategies to slow the progression of age-related macular degeneration (AMD):- What is the effectiveness of antioxidant and zinc supplements on AMD disease progression for people with early AMD at high risk of progression in the context of a randomised controlled trial?

    establish the treatment effect of antioxidant supplementation (the AREDS2 formula) on AMD progression by comparing AREDS2 formula with...

    Research recommendation
    Published
    13 November 2018

  41. Clinical trials should be conducted comparing ticagrelor with prasugrel in people with acute coronary syndromes (ACS).

    Source guidance details Comes from guidance Ticagrelor for the treatment of acute coronary syndromes Number TA236 Date issued

    Research recommendation
    Published
    9 June 2015

  42. Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups would be useful.

    Source guidance details Comes from guidance Ticagrelor for the treatment of acute coronary syndromes Number TA236 Date issued

    Research recommendation
    Published
    9 June 2015

  43. Does the use of barbed sutures for wound closure reduce the incidence of surgical site infection?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  44. Maintaining the benefits of early intervention in psychosis services after discharge:- How can the benefits of early intervention in psychosis services be maintained once service users are discharged after 3 years?

    augmented (step-down) care in community mental health services versus treatment as usual to determine whether the gains of early...

    Research recommendation
    Published
    9 June 2015

  45. Which closure method or technique is the most effective for reducing surgical site infections in patients undergoing emergency surgery?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  46. What is the contribution to clinical effectiveness of the timing of nasal decolonisation and body wash for the prevention of surgical site infection?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  47. What is the clinical effectiveness of preoperative nasal decolonisation using mupirocin in combination with a chlorhexidine body wash in the whole population?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    16 August 2019

  48. What is the effectiveness of decolonisation using alternative interventions in combination with nasal decolonisation in the prevention of surgical site infections when chlorhexidine is contraindicated?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  49. What is the clinical and cost effectiveness of a double application of antiseptic to the skin at the surgical site compared with a single application?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  50. What is the clinical and cost effectiveness of different modes of applying skin antiseptic before incision in the prevention of surgical site infection?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020